The Pharmaceutical Journal
Vol 280 No 7495 p356
29 March 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Parallel traders complain

Parallel traders have complained to the EC that a government-endorsed dual pricing scheme in Spain restricts competition and consumer choice. In Spain, pharmaceutical companies are allowed to charge wholesalers higher prices for medicines that are to be exported than for medicines for domestic use. Pfizer, Lilly, MSD, Sanofi and Janssen have all adopted dual-pricing policies.